These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33975992)

  • 21. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia.
    Rajkumar AP; Poonkuzhali B; Kuruvilla A; Jacob M; Jacob KS
    Int Clin Psychopharmacol; 2013 Jan; 28(1):50-6. PubMed ID: 23104241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum prolactin levels and the acute-phase efficacy in drug-naïve schizophrenia treated with ziprasidone and olanzapine (translated version).
    Wu XL; Wang JH; Hu SH; Tao J
    East Asian Arch Psychiatry; 2012 Mar; 22(1):7-11. PubMed ID: 22447799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.
    Sun L; McDonnell D; von Moltke L
    Clin Ther; 2018 Nov; 40(11):1845-1854.e2. PubMed ID: 30348514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Remission Is not Associated with DRD2 rs1800497 and DAT1 rs28363170 Genetic Variants in Male Schizophrenic Patients after 6-months Monotherapy with Olanzapine.
    Zivkovic M; Mihaljevic-Peles A; Muck-Seler D; Sagud M; Ganoci L; Vlatkovic S; Tudor L; Pivac N; Bozina N
    Psychiatr Danub; 2020; 32(1):84-91. PubMed ID: 32303037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An open-label study of olanzapine in children and adolescents with schizophrenia.
    Quintana H; Wilson MS; Purnell W; Layman AK; Mercante D
    J Psychiatr Pract; 2007 Mar; 13(2):86-96. PubMed ID: 17414684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study.
    Alvarez E; Bobes J; Gómez JC; Sacristán JA; Cañas F; Carrasco JL; Gascón J; Gibert J; Gutiérrez M;
    Eur Neuropsychopharmacol; 2003 Jan; 13(1):39-48. PubMed ID: 12480121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
    Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population.
    Yamashita H; Mori K; Nagao M; Okamoto Y; Morinobu S; Yamawaki S
    J Clin Psychiatry; 2004 Nov; 65(11):1525-30. PubMed ID: 15554767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-desmethyl Olanzapine in Inpatients With Schizophrenia.
    An H; Fan H; Chen S; Qi S; Ma B; Shi J; Wang Z; Yang F
    J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):255-259. PubMed ID: 33814547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential benefits of olanzapine on executive function in schizophrenia patients: Preliminary findings.
    Mehta ND; Won MJ; Babin SL; Patel SS; Wassef AA; Chuang AZ; Sereno AB
    Hum Psychopharmacol; 2020 Jan; 35(1):e2718. PubMed ID: 31837056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
    Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
    Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors.
    Wu TH; Chiu CC; Shen WW; Lin FW; Wang LH; Chen HY; Lu ML
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1889-93. PubMed ID: 18796323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obsessive-compulsive symptoms in patients with schizophrenia: Relationships with olanzapine pharmacological parameters, psychopathology, and quality of life.
    Wu TH; Chiu CC; Chen PY; Huang MC; Chen CH; Shen WW; Lu ML
    Psychiatry Res; 2019 Jun; 276():1-5. PubMed ID: 30981095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
    Kinon BJ; Basson BR; Gilmore JA; Malcolm S; Stauffer VL
    J Clin Psychiatry; 2000 Nov; 61(11):833-40. PubMed ID: 11105736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
    Kinon BJ; Stauffer VL; Kollack-Walker S; Chen L; Sniadecki J
    J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia.
    Kelly DL; Conley RR; Richardson CM; Tamminga CA; Carpenter WT
    Ann Clin Psychiatry; 2003; 15(3-4):181-6. PubMed ID: 14971863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olanzapine and risperidone plasma concentration therapeutic drug monitoring: A feasibility study.
    Law S; Gudbrandsen M; Magill N; Sweetman I; Rose D; Landau S; Flanagan RJ; David AS; Patel MX
    J Psychopharmacol; 2015 Aug; 29(8):933-42. PubMed ID: 26040903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.
    Sun L; Mills R; Sadler BM; Rege B
    J Clin Pharmacol; 2021 Nov; 61(11):1430-1441. PubMed ID: 34018607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcome and olanzapine plasma levels in acute schizophrenia.
    Mauri MC; Steinhilber CP; Marino R; Invernizzi E; Fiorentini A; Cerveri G; Baldi ML; Barale F
    Eur Psychiatry; 2005 Jan; 20(1):55-60. PubMed ID: 15642445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.